**Chapter 4**

*Cystic Fibrosis - Heterogeneity and Personalized Treatment*

[61] Holguin F. Triple CFTR modulator

[62] Vertex provides update on ongoing phase 3 program: Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Boston; 2018. Available from: https://www.businesswire.com/ news/home/20181127005466/en/

[63] Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor). Press release of Vertex Pharamaceuticals London;

2018. Available from: https:// www.businesswire.com/news/ home/20180618005495/en/

therapy for cystic fibrosis. The New England Journal of Medicine.

2018;**379**(17):1671-1672

**52**
